TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 3 Randomized Parallel Group Study Comparing the Efficacy & Safety of SB206 & Vehicle Gel in the Treatment of MC (B-SIMPLE1)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Be 6 months of age or older, and in good general health;~* Have a written informed consent form signed by subject or a parent or legal guardian and an assent form as required;~* Have between 3 and 70 treatable MC at Baseline;~* Female subjects age 9 and above must have a negative UPT at Baseline;~* Female subjects age 9 and above must agree to practice a medically acceptable form of birth control during the study and for 30 days after Week 12/ET1;~* Be willing and able to follow study instructions and likely to complete all study requirements.~Exclusion Criteria:~* Have strongly suggested sexually transmitted MC and do not agree to refrain from sexual activities throughout the study period.~* Are immunosuppressed, have immunodeficiency disorder, or are on immunosuppressive treatment;~* Have significant injury on and/or surrounding MC that may impact ability to treat and count lesions;~* Have received treatment with topical calcineurin inhibitors or steroids on MC or within 2 cm of MC lesions within 14 days prior to Baseline;~* Have received treatment for MC during the 14 days prior to Baseline with podophyllotoxin, imiquimod, cantharidin, sinecatechins, topical retinoids, oral or topical zinc, or other homeopathic or over the counter (OTC) products including, but not limited to, ZymaDerm and tea tree oil, cimetidine and other histamine H2 receptor antagonists (including Zantac);~* Have received surgical procedures related to MC (cryotherapy, curettage, other) within 14 days prior to Baseline;~* Have MC only in periocular area;~* Female subjects who are pregnant, planning a pregnancy or breastfeeding;~* Have known hypersensitivity to any ingredients of SB206 or Vehicle Gel including excipients;~* Have participated in a previous study with a berdazimer sodium product (SB204, SB206, SB208, SB414);~* Have more than 1 family member currently participating in a study with a berdazimer sodium product (SB204, SB206, SB208, SB414).~* Have participated in any other trial of an interventional investigational drug or device within 14 days or concurrent participation in another interventional research study.~* History or presence of clinically significant medical, psychiatric, or emotional condition that, in opinion of the investigator, would compromise the safety of the subject or the quality of the data.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SB206 12% (Type: EXPERIMENTAL): SB206 12% topically once daily
- Placebo (Type: PLACEBO_COMPARATOR): Placebo topically once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Glucocorticosteroid Treatment in the Patients With Chronic Recurrent DILI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Meet with ACG clinic guidelines for diagnostic criteria of chronic DILI;~2. Meet any of the following conditions:~   * serum AST or ALT ≥ 10 fold ULN;~  * serum AST or ALT ≥ 5 fold ULN and TBIL ≥ 2 fold ULN;~  * liver histology indicates bridging necrosis or multiacinar necrosis or moderate or more inflammation or inflammation G3 or more;~3. Women of childbearing age had a negative urine pregnancy test, and the subjects are willing to have no family planning during the study and to take effective measures;~4. Voluntary participation, understanding and signing of informed consent, comply with the requirements of the research;~Exclusion Criteria:~1. Patients with serious pre-existent comorbid conditions (vertebral compression fractures,psychosis,active peptic ulcer, brittle diabetes,uncontrolled hypertension;~2. Patients with intolerances to prednisone;~3. Patients with severe infection receiving antibiotics, anti-fungal,anti-viral therapy;~4. Viral hepatitis,alcoholic or non-alcoholic liver disease,Wilson's disease or other inherited metabolic liver diseases.~5. Pregnancy or desire of pregnancy;~6. Breast-feeding;~7. Liver cancer or other malignant tumor;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Methylprednisolone (Type: EXPERIMENTAL): Participants will receive methylprednisolone from week 0 through week 48 study visit in combination with standard treatment including reduced glutathione, glycyrrhizin, ademetionine, alprostadil,or ursodeoxycholic acid (UDCA) in the first 12 weeks. Participants will then be followed until week 72 study visit.
- Standard Treatment (Type: ACTIVE_COMPARATOR): Participants will only receive standard treatment (namely,routine liver protection drugs) including reduced glutathione, glycyrrhizin, ademetionine, alprostadil,or ursodeoxycholic acid (UDCA) from week 0 through week 12 study visit. Participants will then be followed until week 72 study visit.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Resting-State Neural Connectivity in Patients With Subjective Tinnitus Without Bother

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Men and women between the ages of 45 and 60 years~* Subjective, unilateral or bilateral, non-pulsatile tinnitus of 6 month's duration or greater~* A recent audiogram (within 6 months)~* Either not bothered or bothered a little on the Global Bothersome scale~* Able to give informed consent~* English-speaking~Exclusion Criteria:~* Patients experiencing tinnitus related to cochlear implantation, retrocochlear lesion, or other known anatomic/structural lesions of the ear and temporal bone~* Patients with hyperacusis or misophonia (hyper-sensitivity to loud noises)~* Patients with cardiac pacemakers, intracardiac lines, implanted medication pumps, implanted electrodes in the brain, other intracranial metal objects with the exception of dental fillings, or any other contraindication for MRI scan~* Patients with an acute or chronic unstable medical condition which, in the opinion of the investigator, would require stabilization prior to initiation of magnetic stimulation~* Patients with any active ear disease that, in the opinion of the PI, needs to be further evaluated~* Patients with symptoms of depression as evidenced by a score of 14 or greater on the Beck Depression Inventory or, in the opinion of the psychiatric sub-investigator demonstrates active mood symptoms that meet DSM-IV-TR criteria for Major Depressive Disorder~* Any psychiatric co-morbidity that, in the opinion of the psychiatric sub-investigator, may complicate the interpretation of study results~* Patients with tinnitus related to Workman's Compensation claim or litigation-related event~* Weight over 350 pounds~* A Mini-Mental Status Exam score less than 27~* Patients with a history of claustrophobia~* Inability to lay flat for 2 hours~* Active alcohol and/or drug dependence or history of alcohol and/or drug dependence within the last year~* Any medical condition that, in the opinion of the investigators, confounds study results or places the subject at greater risk~* Unable to provide informed consent~* Any exclusions from radiology screening Currently Pregnant

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Slightly or Non-Bothered Tinnitus Group (Type: None): Identified by a Tinnitus Handicap Index \<36 and a subjective description of their tinnitus as no or slight bother.~A control group has been collected through a different study, i.e. no controls will be recruited in this study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy & Safety of Orally Administered Valsartan/Amlodipine Combo Therapy vs Amlodipine Monotherapy in Patients With Stage II Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older.~* Moderate to severe high blood pressure. This is defined as a systolic pressure (the top number) greater than or equal to 160 mmHg and less than 200 mmHg.~Exclusion Criteria:~* History of allergy or hypersensitivity to ARBs, CCBs, thiazide diuretics~* Inability to stop all prior blood pressure medications safely~* Systolic BP ≥ 200 mmHg and/or diastolic BP ≥ 120 mmHg~* Controlled blood pressure (systolic BP \< 140 mmHg) taking more than 3 antihypertensive medications at screening~* Systolic BP ≥ 140 mmHg and \< 180 mmHg taking more than two antihypertensive medications at screening~* Systolic BP ≥ 180 mmHg taking more than one antihypertensive medication at screening~* History of stroke, angioplasty, coronary artery bypass graft surgery, heart attack or unstable angina~* Type 1 diabetes~* Poorly controlled Type 2 diabetes~* History of heart failure~* Arrhythmia~* Significant valvular heart disease~* Active gout~* History of autoimmune diseases~* History of multiple drug allergies~* Liver disease~* Pancreatic injury within 1 year of screening~* Evidence of kidney impairment or history of dialysis~* Any surgical or medical condition which might alter the absorption, distribution, metabolism, or excretion of any drug. This could include currently active gastritis, ulcers, or gastrointestinal/rectal bleeding, or urinary tract obstruction.~* Women of child-bearing potential (WOCBP), defined as all women physiologically capable of becoming pregnant, would be excluded UNLESS they are post-menopausal, surgically sterile OR are using acceptable methods of contraception. The use of hormonal contraceptives is not allowed~* Pregnant or nursing (lactating) women~* History of malignancy of any organ system within the past five years~* Any severe, life-threatening disease within the past five years~* History of drug or alcohol abuse within the last 2 years.~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vaccine Biotherapy of Cancer: Autologous Tumor Cells and Dendritic Cells

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Recurrent or metastatic melanoma as defined by stage IV disease (distant metastases), or any recurrent melanoma manifested by lymph node metastases or soft tissue nodules~* ECOG Performance status of 0-2~* Satisfactory medical condition for treatment in a phase I-II trial of anticancer therapy~* Age \> 16 years~* Venous access for leukopheresis procedure to obtain peripheral blood lymphocytes to generate dendritic cells.~* Serum pregnancy test must be negative for women of childbearing potential.~Exclusion Criteria:~* Active central nervous system metastases~* Known autoimmune disease or disease process that involves the use of immunosuppressive therapy.~* Underlying cardiac disease associated with New York Heart Association class III or IV function, or unstable angina related to atherosclerotic cardiovascular disease.~* Ongoing transfusion requirements, no significant hepatic or renal dysfunction, creatinine \< 2.0 mg/dl, bilirubin \< 2.0 mg/dl, albumin \> 3.0 mg/dl, hematocrit \> 25, platelets \> 100,000.~* Active infection or other active medical condition that could be eminently life threatening, including no active blood clotting or bleeding diathesis.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Efficacy of LAI When Added to Multi-drug Regimen Compared to Multi-drug Regimen Alone

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Be continually positive for MAC on sputum culture while adhering to a multi-drug treatment regimen for a minimum duration of 6 months which is either ongoing or was completed no more than 12 months before screening~2. Be diagnosed with MAC NTM lung infection with evidence of nodular bronchiectasis and/or fibrocavitary disease by chest CT~3. Be willing to adhere to multi-drug treatment regimen during the course of the study~Exclusion Criteria:~1. Patients with cystic fibrosis~2. Positive pregnancy test or lactation at screening. All women of child bearing potential will be tested. Women not of childbearing potential are defined as postmenopausal (i.e., amenorrheic for at least 1 year), or surgically or naturally sterile.~3. Active pulmonary tuberculosis requiring treatment at screening~4. History of lung transplantation~5. Prior exposure to LAI (including clinical study).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Multi-drug Regimen (Type: NO_INTERVENTION): Participants received their already prescribed anti-mycobacterial regimen (based on the 2007 American Thoracic Society/Infectious Diseases Society of America \[ATS/IDSA\] Guidelines)
- LAI + Multi-drug Regimen (Type: EXPERIMENTAL): Participants received LAI 590 mg QD in addition to their already prescribed anti-mycobacterial regimen (based on the 2007 ATS/IDSA Guidelines)~LAI 590 mg QD, administered by inhaling drug product that had been aerosolized in an eFlow nebulizer over approximately 14 minutes

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~1. Type 2 diabetes mellitus~2. GFR\<60 ml/min~3. HbA1c \>=7.0% to \<= 10%~4. Age \>= 18 years~5. BMI \<=45 kg/m2~6. Signed and dated written informed consent~Exclusion criteria:~1. Myocardial infarction, stroke or TIA within 3 months prior to informed consent~2. Renal impairment requiring dialysis~3. Bariatric surgery~4. Impaired hepatic function~5. Treatment with glitazones, GLP-1 analogues, DPP-4 inhibitors~6. Treatment with anti-obesity drugs~7. Treatment with SU, glinides and metformin 8 weeks prior to informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Linagliptin (Type: EXPERIMENTAL): 52 weeks treatment
- Placebo (Type: PLACEBO_COMPARATOR): First 12 weeks of treatment
- Glimepiride (Type: ACTIVE_COMPARATOR): Placebo patients switch to glimepiride after 12 weeks (40 weeks treatment)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Of The Mechanism Of Action Of CP-690,550 In The Skin Of Subjects With Moderate To Severe Chronic Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults over 18 years of age with a diagnosis of chronic moderate to severe plaque psoriasis for at least 12 months; in generally good health; on stable dose of non-prohibited medications; able to stop current psoriasis therapy (systemic or topical) for several weeks prior to and during study participation.~Exclusion Criteria:~* Serious underlying disease including viral disorders such as hepatitis or HIV or skin condition that would interfere with skin biopsies or evaluation of psoriasis; conditions that could interfere with drug absorption after oral administration; history of malignancy or auto-immune disease.~* Use of oral or injected corticosteroids (steroids).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): None
- Cohort 2 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase III Insulin Add-On Asia Regional Program - ST

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must have type 2 diabetes with inadequate glycemic control, defined as HbA1c ≥ 7.5% and ≤ 11.0% obtained at screening visit~* Subjects must be taking a stable mean dose of ≥ 20 IU injectable insulin daily for at least 8 weeks prior to enrollment~Inclusion criteria for randomization:~HbA1c ≥ 7.5 and ≤ 10.5% at Day -14~Exclusion Criteria:~* Treatment with more than two oral antidiabetic (OAD) agents within 6 weeks of Enrollment~* History of diabetic ketoacidosis of hyperosmolar nonketotic coma~* Clinically diagnosed Type 1 diabetes mellitus~* Congestive heart failure defined as New York Heart Association (NYHA) stage III and IV~* Severe uncontrolled hypertension defined as systolic blood pressure (SBP) ≥ 180 mmHg and/or diastolic blood pressure (DBP) ≥ 110 mmHg~* History of unstable or rapidly progressing renal disease~* History of severe hepatobiliary disease~* Mallingancy within 5 years of the screening/enrollment visit

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1: Dapagliflozin (Type: EXPERIMENTAL): Dapagliflozin 10 mg oral Tablet once daily for 24 weeks + Background Insulin
- Group 2: Dapagliflozin Placebo (Type: PLACEBO_COMPARATOR): Dapagliflozin Placebo 0 mg oral Tablet once daily for 24 weeks + Background Insulin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: On the Move: Optimizing Participation in Group Exercise

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* 65 years of age or older~* resident of University of Pittsburgh Medical Center Independent Living Facility or senior housing site~* Ambulate independently for household distance (may use a straight cane)~Exclusion Criteria:~* non English speaking~* impaired cognition defined as unable to follow 2 step commands~* plans to leave area in next 4 months~* progressive neuromuscular disorder~* any acute illness or medical condition that is not stable~* inappropriate response on 6 minute walk test

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- On the Move Exercise - exercise leader (Type: EXPERIMENTAL): On the Move group exercise - 2 times per week for 12 weeks. Each session lasts approximately 1 hour. Timing and coordination exercises to improve walking. Led by exercise leader
- Standard program - exercise leader (Type: ACTIVE_COMPARATOR): Standard impairment based seated group exercise program. 2 times per week for 12 weeks, approximately 1 hour class. Led by exercise leader
- On the Move - staff activity personnel (Type: ACTIVE_COMPARATOR): On the Move group exercise - 2 times per week for 12 weeks. Each session lasts approximately 1 hour. Timing and coordination exercises to improve walking. Led by activity personnel.
- Standard - staff activity personnel (Type: ACTIVE_COMPARATOR): Standard impairment based seated group exercise program. 2 times per week for 12 weeks, approximately 1 hour class. Led by staff activity personnel

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Testing the Effectiveness of Henna on Managing PPE

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult cancer patients (\>18)~* Patients receiving capecitabine and/or PLD as monotherapy or in combination with other agents~* Patients that will experience PPE grade 1 or above~* Willing to participate~* Ability to complete the psychometric assessments.~* A performance status of two or less on the Eastern Cooperative Oncology Group (ECOG)~Exclusion Criteria:~* Patients with hypersensitivity to natural henna.~* Patients with pre-existing dermatological condition affecting the hands or feet that may limit the interpretation of results~* Patients on Pyridoxine or nicotine patches~* Patients with a previous history of PPE~* Patients whose chemotherapy was discontinued for more than a week

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Henna arm (Type: EXPERIMENTAL): Based on the treatment protocol for this study the patients will receive the henna treatment for 4 weeks (supervised treatment for first week and then unsupervised sessions twice a week). The treatment will include the application of the henna mixture (paste) (40gr natural henna and 40ml of purified water) to the affected areas (feet or/and hands) and wear socks or/and gloves. The treatment session will last for 1 hour and then the mixture will be rinsed with fresh water.
- Placebo (Type: PLACEBO_COMPARATOR): Based on the treatment protocol for this study the patients in this arm will receive the henna placebo treatment for 4 weeks (supervised treatment for first week and then unsupervised sessions twice a week). The treatment will include the application of the henna placebo mixture (paste) (40gr placebo henna and 40ml of purified water) to the affected areas (feet or/and hands) and wear socks or/and gloves. The treatment session will last for 1 hours and then the mixture will be rinsed with fresh water.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete